Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
08:00am, Tuesday, 13'th Feb 2024
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, Febr
This late-January stock-trading pattern has been a winner in 30 of the past 38 years
03:57pm, Thursday, 25'th Jan 2024
The stock market, as measured by the S&P 500 index SPX, has broken out strongly to the upside, trading at new intraday and closing highs. The breakout came on Jan. 19, over the 4,800 level.
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
05:13pm, Monday, 22'nd Jan 2024
Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little
Why Is Esperion Therapeutics (ESPR) Stock Down 24% Today?
08:50am, Friday, 19'th Jan 2024
Esperion Therapeutics (NASDAQ: ESPR ) stock is falling on Friday after the pharmaceutical company announced details for a public offering of its shares. This public offering has Esperion Therapeutics
Esperion Is Sitting On A Potential Blockbuster Drug
09:00am, Sunday, 14'th Jan 2024
Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer al
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
12:47pm, Thursday, 04'th Jan 2024
Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.
Esperion resolves legal dispute with Daiichi Sankyo ahead of likely European drug approval
12:15pm, Wednesday, 03'rd Jan 2024
Esperion Therapeutics has reached a deal with Daiichi Sankyo to resolve a commercial dispute with an amendment to their ongoing collaboration. Daiichi Sankyo Europe GmbH, the company's European arm
Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?
12:48pm, Thursday, 07'th Dec 2023
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion: Navigating The 'Bemp' Of Success Amidst Market Waves And Legal Tides
10:45pm, Sunday, 12'th Nov 2023
Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US an
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
02:17pm, Wednesday, 08'th Nov 2023
Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
08:16am, Tuesday, 07'th Nov 2023
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.81 per share a year ago.
Trading Penny Stocks This Week? 4 To Watch With Big News
10:25am, Tuesday, 29'th Aug 2023
Are you trading penny stocks this week? Chances are that if you're reading this article, you have some intention of finding more info on cheap stocks.
Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone Litigation
08:46am, Tuesday, 29'th Aug 2023
Esperion reported Q2 bempedoic acid revenue of $20.3M; we expect the bempedoic acid to surpass the 2023 consensus numbers. The ongoing Daiichi litigation poses a significant weight on Esperion's stock
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
03:12pm, Monday, 28'th Aug 2023
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created t
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Monday, 28'th Aug 2023
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President
